Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of COVID-19 on Maternal and Neonatal Outcomes
Sponsor: Johns Hopkins University
Summary
The novel coronavirus (SARS-CoV-2) infection (COVID-19) has caused a worldwide pandemic. There is still much that is unknown regarding the virus, especially its effects on pregnancy, the fetus, and the neonate. This study seeks to evaluate adverse pregnancy and neonatal outcomes related to COVID-19 infection. The FDA has authorized emergency use authorization for the SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccines from Pfizer and Moderna. Pregnant women were excluded from the Phase III clinical trials of the mRNA vaccines. There are no studies that have evaluated functional antibody responses, antibody reactivity to variant viruses, T cell frequencies or activity, or protection against infection or development of COVID-19. Having a more detailed understanding of how pregnancy and lactation alters the longevity, specificity, and activity of antiviral antibody and T cell-mediated immune responses to COVID-19 mRNA vaccines is essential for the FDA to inform future recommendations and regulation of these vaccines.
Key Details
Gender
FEMALE
Age Range
14 Years - 55 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2020-04-13
Completion Date
2028-05-05
Last Updated
2025-05-09
Healthy Volunteers
Yes
Conditions
Interventions
mRNA COVID-19 vaccine (Pfizer or Moderna)
mRNA vaccine received at any time during pregnancy course
Locations (1)
Johns Hopkins Hospital
Baltimore, Maryland, United States